Kyowa Kirin North America (KKNA) is working to address the racial disparities affecting the care and outcomes of African American patients with Cutaneous T-cell Lymphoma (CTCL).
CTCL is a rare form of blood cancer that first appears on the skin and is often mistaken for more common dermatologic conditions. CTCL can affect the skin as well as lymph nodes, blood cells and internal organs.
Approximately 30,000 people in the U.S. and Canada are affected by CTCL. On average, it takes two to seven years for a patient with CTCL to be diagnosed.
In 2018, KKNA won FDA approval for the CCR4 receptor antagonist Poteligeo (mogamulizumab-kpkc), treating adults with two CTCL subtypes: relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
To learn more about the company’s efforts related to CTCL, we spoke with Lauren Walrath, vice president of public affairs and sponsor of Kyowa Kirin North Ame…